Navigation Links
FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
Date:7/31/2009

d involuntary movements, and abnormal movements of the eyes.

This is not a complete list of all possible side effects. Ask your doctor or treatment team if you have any questions or want more information.

If you have any questions about INVEGA(R) SUSTENNA(TM) or your therapy, talk with your doctor.

About INVEGA(R) SUSTENNA(TM)

INVEGA SUSTENNA is approved for the acute and maintenance treatment of schizophrenia. It is the first once-monthly, long-acting, injectable atypical antipsychotic approved for this use in the U.S. INVEGA SUSTENNA is available in milligrams (mg) of paliperidone palmitate in dose strengths of 39 mg, 78 mg, 117 mg, 156 mg and 234 mg. Please be aware that clinical trial data presented at medical meetings were often reported as milligram equivalents (mg eq.) to paliperidone. Each dose of paliperidone palmitate is equivalent to a specific dose of paliperidone (39 mg, 78 mg, 117 mg, 156 mg and 234 mg of paliperidone palmitate is equivalent to 25 mg, 50 mg, 75 mg, 100 mg and 150 mg of paliperidone, respectively).

The pre-filled syringes require no reconstitution or refrigeration. Patients initiate treatment with two injections administered in the deltoid muscle one week apart (Day 1 at 234 mg and Day 8 at 156 mg), followed by injections every month thereafter administered in either the deltoid or gluteal muscle.

INVEGA SUSTENNA was developed utilizing Elan Drug Technologies' proprietary NanoCrystal(R) Technology. Using this technology increases the rate of dissolution and enables the formulation of an aqueous suspension for once-monthly intramuscular administration. INVEGA SUSTENNA is manufactured by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, in the U.S.

About J&JPRD

INVEGA SUSTENNA was developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&
'/>"/>

SOURCE Janssen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... Mi40x , the latest guide from ... people how they can use a simple 4-minute trick to ... of weeks has caught the attention of Shane Michaels, prompting ... the most well-known bodybuilders in the industry, and if he ... that in itself is a testament to how effective this ...
(Date:8/22/2014)... 2014 Paying tuition and other related ... coming year for four nurse educators pursuing advanced degrees, ... for Nursing Foundation for Nursing Education . This year’s ... $10,000 more than in 2013, thanks to these named ... Elizabeth Isaac Marcil Endowment Funds, both donated by Kathy ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Mueller Sports ... Plantar Fasciitis, an exciting new product that provides non-drug ... to stay active while you heal. The package includes ... truly a new technology – it is not kinesiology ... FasciaDerm® PFTape™ System for Plantar Fasciitis is ...
(Date:8/22/2014)... NJ. August 22, 2014. A new study ... persons with multiple sclerosis (MS) may be able ... The study was epublished ahead of print on ... Helen Genova, Hali Griswold, Nancy D. Chiaravalloti & ... persons with multiple sclerosis doi: 10.3233/NRE-141113). Self-awareness is ...
Breaking Medicine News(10 mins):Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... for most commonly used infection-fighters, , MONDAY, Nov. 2 ... raise the risk for most birth defects, though there ... which is the most commonly used antibiotic during pregnancy, ... widely prescribed antibiotics, were not associated with increased risk ...
... TO CORRESPONDENTS , SILVER SPRING, Md., Nov. 2 ... released a listing of eight recent consumer health information ... can be accessed from the agency,s Web page for ... sign-up for e-mail notices of new consumer updates on ...
... , , Highest Levels of BPA Were Detected in ... Dietary Exposure Could Approach Levels Shown to Cause Harm in Animal ... , YONKERS, N.Y., Nov. 2 Consumer Reports, latest tests ... found that almost all of the 19 name-brand foods tested contain ...
... Infants born to women who received influenza vaccine during ... born to unvaccinated mothers, according to preliminary results of ... Medicine. The team presented the study October 29 at ... of America in Philadelphia. Influenza is a ...
... the 2010 Medicare Physician Fee Schedule will restrict life-saving ... wait times to receive care, and cause life threatening ... serious illnesses. "These short sighted, unfounded and ... to cutting-edge imaging scans, and delay diagnosis of cancers ...
... study finds, , MONDAY, Nov. 2 (HealthDay News) -- ... linked to aggression in young children. , This research, ... of Pediatrics & Adolescent Medicine , found that direct ... viewing in the household were both associated with increased ...
Cached Medicine News:Health News:CDC Study Links 2 Antibiotics to Birth Defects 2Health News:CDC Study Links 2 Antibiotics to Birth Defects 3Health News:CDC Study Links 2 Antibiotics to Birth Defects 4Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 2Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 3Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 2Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 3Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 4Health News:Consumer Reports: Tests Find Wide Range of Bisphenol A in Canned Soups, Juice, and More 5Health News:Flu vaccine given to women during pregnancy keeps infants out of the hospital 2Health News:Imaging cuts in Medicare fee schedule: An access catastrophe and danger to patients 2Health News:Imaging cuts in Medicare fee schedule: An access catastrophe and danger to patients 3Health News:TV May Increase Aggression in Toddlers 2Health News:TV May Increase Aggression in Toddlers 3
(Date:8/22/2014)... -- Research and Markets  has announced the addition ... & Technologies" report to their offering. ... or you wish to expand your product line, you,ll ... The authors know you want to make effective product ... generate improved revenues and take market share from your ...
(Date:8/22/2014)... 22, 2014   Zacks Equity Research highlights Epizyme (Nasdaq: ... Day and Panera (Nasdaq: PNRA - Free Report ) as ... analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ), ... SHPG - Free Report ). Here is a ... the Day : The biotech bull market is ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 ... of Hospital TVs Today Lincor announced general ... Patient Engagement solution that delivers a range of education, ... sets.      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , ... in defining point of care patient engagement to bedside ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... Medical Imaging (RMI) in Flint announced today that it is ... Breast Magnetic Resonance Imaging (MRI) by the American College of ... the Breast MRI Accreditation Program to recognize imaging ... for Breast MRI. RMI received this new distinction after a ...
... Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today ... trial program for APD597 (JNJ-38431055) under its collaboration with ... APD597 and has notified Arena that it is terminating ... GPR119 agonist intended for the treatment of type 2 ...
Cached Medicine Technology:Exciting Healthcare News for Women of Mid Michigan 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 2Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 3Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 4Arena Pharmaceuticals Provides Update on GPR119 Portfolio for Type 2 Diabetes 5
Reusable shielded cable...
... The STREP A OIA MAX test ... of Group A Strep with a simple, ... minutes. This combination of performance, speed, and ... care while reducing overall costs for diagnosing ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... a high performance assay for the undifferentiated ... with a simple, easy-to-use test that provides ... Assay advantages include superior performance with mucoid ... 14-day viral culture enables you to decrease ...
Medicine Products: